Business Description
ImmuPharma PLC
NAICS : 325412
ISIN : GB0033711010
Description
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.66 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.8 | |||||
| 3-Year EPS without NRI Growth Rate | 37.7 | |||||
| 3-Year FCF Growth Rate | 39.4 | |||||
| 3-Year Book Growth Rate | -57.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.68 | |||||
| 9-Day RSI | 35.64 | |||||
| 14-Day RSI | 41.13 | |||||
| 6-1 Month Momentum % | -58.33 | |||||
| 12-1 Month Momentum % | -33.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | |||||
| Quick Ratio | 1.6 | |||||
| Cash Ratio | 0.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 3612.86 | |||||
| Net Margin % | 3517.14 | |||||
| FCF Margin % | 2298.77 | |||||
| ROE % | -134.68 | |||||
| ROA % | -73.33 | |||||
| ROIC % | -117.16 | |||||
| ROC (Joel Greenblatt) % | -1501.57 | |||||
| ROCE % | -157.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.02 | |||||
| Price-to-Tangible-Book | 0.05 | |||||
| EV-to-EBIT | -1.57 | |||||
| EV-to-EBITDA | -1.58 | |||||
| EV-to-Revenue | -64.27 | |||||
| EV-to-FCF | -3.05 | |||||
| Earnings Yield (Greenblatt) % | -63.7 | |||||
| FCF Yield % | -33.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImmuPharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | -0.081 | ||
| EPS (TTM) (€) | -0.008 | ||
| Beta | -10.93 | ||
| Volatility % | 6293.03 | ||
| 14-Day RSI | 41.13 | ||
| 14-Day ATR (€) | 0.005244 | ||
| 20-Day SMA (€) | 0.0119 | ||
| 12-1 Month Momentum % | -33.33 | ||
| 52-Week Range (€) | 0.0002 - 0.04 | ||
| Shares Outstanding (Mil) | 416.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmuPharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmuPharma PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ImmuPharma PLC Frequently Asked Questions
What is ImmuPharma PLC(FRA:25I)'s stock price today?
The current price of FRA:25I is €0.00. The 52 week high of FRA:25I is €0.04 and 52 week low is €0.00.
When is next earnings date of ImmuPharma PLC(FRA:25I)?
The next earnings date of ImmuPharma PLC(FRA:25I) is 2025-06-05 Est..
Does ImmuPharma PLC(FRA:25I) pay dividends? If so, how much?
ImmuPharma PLC(FRA:25I) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers